NCT05973864View on ClinicalTrials.gov

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 11, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Triple Negative Breast Neoplasms
Interventions
DRUG

Pembrolizumab injection

On Day 1 of each cycle for a total of 9 cycles; intravenous (IV) infusion

DRUG

Capecitabine tablets

1250 mg/m² BID, on days 1-14 of each 21-day cycle; 8 cycles Dose reduction at 825 mg/m² BID during radiotherapy if indicated

RADIATION

Local radiotherapy

Local radiotherapy will be performed as per standard practice if indicated.

Trial Locations (8)

31130

RECRUITING

Clinique de La Croix du sud, Quint-Fonsegrives

51100

RECRUITING

Institut Godinot, Reims

54519

RECRUITING

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

64109

RECRUITING

Centre Hospitalier de la Côte Basque, Bayonne

75005

RECRUITING

Institut Curie, Paris

92210

RECRUITING

Institut Curie, Saint-Cloud

Unknown

RECRUITING

CHD Vendee, La Roche-sur-Yon

RECRUITING

Institut Claudius Regaud, IUCT Oncopole, Toulouse

All Listed Sponsors
lead

UNICANCER

OTHER